Effects of various photoradiation regimens on the antitumor efficacy of photodynamic therapy for R3230AC mammary carcinomas
- PMID: 2171760
Effects of various photoradiation regimens on the antitumor efficacy of photodynamic therapy for R3230AC mammary carcinomas
Abstract
Clinical photodynamic therapy consists of the systemic administration of a derivative of hematoporphyrin (Photofrin II) followed by exposure of malignant lesions to continuous visible laser irradiation. We investigated the effects of various modifications of laser light delivery on the efficacy of photodynamic therapy in controlling R3230AC mammary tumor growth. We observed a significant delay in growth (from initial to 2 times initial volume) of tumors exposed to periodic irradiation (100 mW/cm2/0.25 h, 1-h dark interval, 100 mW/cm2/0.25 h; total fluence, 180 J/cm2), compared to untreated controls or to tumors receiving continuous irradiation at the same total fluence. Other periodic light treatment regimens, consisting of 3-, 6-, or 24-hr dark intervals, delayed tumor growth but not significantly more than continuous irradiation at the same fluence. A biochemical basis was sought by comparing continuous versus periodic irradiation for effects on mitochondrial or cytosolic enzymes in vivo. Although both cytochrome c oxidase and pyruvate kinase activities were reduced dramatically during the first 24 h by continuous or periodic irradiation schemes, recovery of enzyme activity to initial levels took longer after the periodic irradiation protocol (168 h), compared to the continuous irradiation regimen (72 h). We observed a significantly greater delay in the growth of tumors exposed to 50 mW/cm2/2 h continuously, compared to controls or to tumors exposed to the same total fluence but with light delivered at 100 or 200 mW/cm2. The data presented here indicate that the efficacy of photodynamic therapy could be significantly increased by modifications in the delivery of photoradiation.
Similar articles
-
Effects of laser photodynamic therapy on tumor phosphate levels and pH assessed by 31P-NMR spectroscopy.Cancer Biochem Biophys. 1989 Oct;10(4):319-28. Cancer Biochem Biophys. 1989. PMID: 2533522
-
The effect of fluence rate on tumor and normal tissue responses to photodynamic therapy.Photochem Photobiol. 1998 Apr;67(4):462-6. Photochem Photobiol. 1998. PMID: 9559590
-
Comparison of fluorescence and photodynamic activities of whole hematoporphyrin derivative and its enriched active components.J Natl Cancer Inst. 1985 Dec;75(6):1135-40. J Natl Cancer Inst. 1985. PMID: 2933546
-
Hematoporphyrin derivative-induced photosensitivity of mitochondrial succinate dehydrogenase and selected cytosolic enzymes of R3230AC mammary adenocarcinomas of rats.Cancer Res. 1984 Apr;44(4):1483-8. Cancer Res. 1984. PMID: 6231099
-
Photosensitizing effects of hematoporphyrin derivative and photofrin II on the plasma membrane enzymes 5'-nucleotidase, Na+K+-ATPase, and Mg2+-ATPase in R3230AC mammary adenocarcinomas.Cancer Res. 1988 Jun 15;48(12):3360-6. Cancer Res. 1988. PMID: 2836053
Cited by
-
Photoacoustic visualization of the fluence rate dependence of photodynamic therapy.Biomed Opt Express. 2020 Jul 10;11(8):4203-4223. doi: 10.1364/BOE.395562. eCollection 2020 Aug 1. Biomed Opt Express. 2020. PMID: 32923037 Free PMC article.
-
Effects of light fractionation and different fluence rates on photodynamic therapy with 5-aminolaevulinic acid in vivo.Br J Cancer. 2003 May 6;88(9):1462-9. doi: 10.1038/sj.bjc.6600910. Br J Cancer. 2003. PMID: 12778078 Free PMC article.
-
Repetitive 5-aminolevulinic acid-mediated photodynamic therapy on human glioma spheroids.J Neurooncol. 2003 May;62(3):243-50. doi: 10.1023/a:1023362011705. J Neurooncol. 2003. PMID: 12777075
-
Singlet oxygen luminescence as an in vivo photodynamic therapy dose metric: validation in normal mouse skin with topical amino-levulinic acid.Br J Cancer. 2005 Jan 31;92(2):298-304. doi: 10.1038/sj.bjc.6602331. Br J Cancer. 2005. PMID: 15655542 Free PMC article.
-
Current status of photodynamic therapy in oncology.Drugs. 1994 Oct;48(4):510-27. doi: 10.2165/00003495-199448040-00003. Drugs. 1994. PMID: 7528127 Review.